Pure MHC to Partner with AbbVie on Oncology Research
Monday, January 09, 2017
PURE MHC LEVERAGES THE HUMAN IMMUNE SYSTEM TO CREATE NOVEL THERAPEUTICS
Pure MHC, LLC is a platform technology company with expertise in disease-specific target identification, and validation as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases as well as allergy. Pure MHC identifies and leverages the same disease targets for drug discovery that the immune system naturally uses to identify foreign or aberrant protein targets in cancerous, infected, or unhealthy cells.
HLA proteins act as an alarm system for detection of cancerous and infected cells by presenting a foreign or aberrant peptide to T cells.
A therapeutic response can be generated with the use of T-cell receptor mimic (TCRm) antibodies that bind HLA/peptide complexes which are called T-cell receptor mimics (TCRm).